RGS19

Across TCGA pan-cancer cohorts, RGS19 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RGS19 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RGS19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RGS19 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, COAD, and PDAC are the cancer types where RGS19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.947	0.166	.010	43	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	42	view →
PDAC	DFS	Quartile	II,III,IV	0.611	0.887	.002	18	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.019	4	view →
LSCC	DFS	Median	All	0.907	0.464	.009	2	view →
LUAD	DFS	Tertile	All	0.643	0.939	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RGS19–HNSC (OS)

Open the HNSC breakdown →